New drug development: An introduction to clinical trials: Second edition

New Drug Development: An Introduction to Clinical Trials: Second Edition

Volumn , Issue , 2010, Pages 1-256

  Turner, J Rick ^a  

^a IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900944134     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-6418-2     Document Type: Book

References (111)

1. Bader GD, Enright AJ, 2005, Intermolecular interactions and biological pathways. In Baxevanis AD, Ouellette BFF (Eds), Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, 3rd Edition. Hoboken, NJ: Wiley.
2. Borer JS, Pouleur H, Abadie E, et al., 2007, Cardiovascular safety of drugs not intended for cardiovascular use: Need for a new conceptual basis for assessment and approval. European Heart Journal, 28:1904-1909.
3. Brass EP, Lewis RJ, Lipicky R, Murphy J, Hiatt WR, 2006, Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular risk. Clinical Pharmacology and Therapeutics, 75:165-172.
4. Brun P, 2006, Blinding of drug products. In Monkhouse DC, Carney CF, Clark JL (Eds), Drug Products for Clinical Trials, 2nd Edition. Boca Raton: Taylor & Francis, 149-172.
5. Buncher CR, Tsay J-Y (Eds), 2006, Statistics in the Pharmaceutical Industry, 3rd Edition. Boca Raton: Chapman & Hall/CRC.
6. Cabell C, 2009, Patient recruitment: Are we looking in the right place? International Pharmaceutical Industry, Summer issue, 38-41.
7. Campbell MJ, Machin D, 1999, Medical Statistics: A Commonsense Approach, 3rd Edition. Chichester, UK: Wiley.
8. Caveney E, Turner JR, 2009, Assessing cardiovascular safety during the development of new antidiabetic therapies for Type 2 diabetes: A review of FDA guidance. DIA Global Forum, December issue, 42-45.
9. Caveney E, Turner JR, 2010, Regulatory landscapes for future antidiabetic drug development (Part I): FDA guidance on assessment of cardiovascular risks. Journal for Clinical Studies, January issue, 34-36.
10. Chow S-C, Chang M, 2007, Adaptive Design Methods in Clinical Trials. Boca Raton: Chapman & Hall/CRC.
11. Chow S-C, Liu J-P, 2004, Design and Analysis of Clinical Trials: Concepts and methodologies. Boca Raton: CRC/Taylor Francis
12. Cohen MR (Ed), 2007, Medication Errors, 2nd Edition. Washington, DC: American Pharmacists Association.
13. Dayan CM, Wraith DC, 2008, Preparing for first-in-man studies: The challenges for translational immunology post-TGN1412. Clinical and Experimental Immunology, 151:231-234.
14. De Ponti F, 2008, Pharmacological and regulatory aspects of QT prolongation. In Vaz RJ, Klabunde T (Eds), Antitargets: Prediction and Prevention of Drug Side Effects. Weinheim, Germany: Wiley-VCH.
15. Derenzo E, Moss J, 2006, Writing Clinical Research Protocols: Ethical Considerations. San Diego: Elsevier.
16. Diamond GA, Bax L, Kaul S, 2007, Perspective: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine, 147:578-581.
17. Durham TA, Turner JR, 2008, Introduction to statistics in Pharmaceutical Clinical Trials. London: Pharmaceutical Press.
18. Ellenberg SS, Fleming, De Mets DL, 2003, Data Monitoring Committees in Clinical Trials: A Practical Perspective. Hoboken, NJ: Wiley.
19. Faich GA, Stemhagen A, 2005, Cardiac arrhythmia assessments in Phase IV clinical studies. In Morganroth JM, Gussak I (Eds), Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical Research and Drug Development. Totowa, NJ: Humana Press, 229-237.
20. FDA, 2008, The Sentinel Initiative: National Strategy for Monitoring Medical Product Safety. [See www.fda.gov]
21. FDA, 2009, Guidance for Industry Drug-induced Liver Injury: Premarketing Clinical Evaluation. [See www.fda.gov]
22. Fletcher RH, Fletcher SW, 2005, Clinical Epidemiology, 4th Edition. Philadelphia: Lippincott Williams & Wilkins.
23. Friedman LK, Furberg CD, De Mets DL, 1998, Fundamentals of Clinical Trials, 3rd Edition. New York, NY: Springer
24. Gad SC, 2006, Statistical and Experimental Design for Toxicologists and Pharmacologists, 4th Edition. Boca Raton: CRC Press.
25. Gardner MJ, Altman DG, 1986, Estimation rather than hypothesis testing: Confidence intervals rather than p-values. In Gardner MJ, Altman DG (Eds), Statistics with Confidence. London: British Medical Association.
26. Good PI, 2006, A Manager's Guide to the Design and Conduct of Clinical Trials, 2nd Edition. Hoboken, NJ: Wiley-LISS.
27. Gough J, Hamrell M, 2009, Standard Operating Procedures (SOPs): Why companies must have them, and why they need them. Drug Information Journal, 43:69-74.
28. Gough J, Hamrell M, 2010, Standard Operating Procedures (SOPs): how companies can determine which documents they must put in place. Drug Information Journal, 44:49-54.
29. Holmes MR, Ramkissoon KR, Giddings MC, 2005, Proteomics and protein identification. In Baxevanis AD, Ouellette BFF (Eds), Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, 3rd Edition. Hoboken, NJ: Wiley-Interscience, 445-572.
30. Hwang IK, Lan KKG, 2006, Interim analysis and adaptive design in clinical trials. In Buncher CR, Tsay J-Y (Eds), Statistics in the Pharmaceutical Industry, 3rd Edition. Boca Raton: Chapman & Hall/CRC, 245-284.
31. Institute of Medicine of the National Academies, 2007a, The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academies Press.
32. Institute of Medicine of the National Academies, 2007b, Preventing Medication Errors. Washington, DC: National Academies Press.
33. Jaishankar R, 2009, Patient recruitment and retention in clinical trials. International Pharmaceutical Industry, Spring issue, 26-28.
34. Kalow W, 2005, Historical aspects of pharmacogenetics. In Kalow W, Meyer UA, Tyndale RF (Eds), Pharmacogenomics, 2nd Edition. Boca Raton: Taylor & Francis, 1-11.
35. Kannel WB, Sorlie P, 1975, Hypertension in Framingham. In Paul O (Ed), Epidemiology and Control of Hypertension. New York: Grune & Stratton/Intercontinental Medical Book Corporation.
36. Katz DL, 2001, Clinical Epidemiology and Evidence-based Medicine: Fundamental Principles of Clinical Reasoning and Research. Thousand Oaks: Sage Publications.
37. Kay R, 2005, Statistical Thinking in Clinical Trials. Training course given in Chapel Hill, NC, May 2005.
38. Kay R, 2007, Statistical Thinking for Non-statisticians in Drug Regulation. Chichester, UK: Wiley.
39. Machin D, Campbell MJ, 2005, Design of Studies for Medical Research. Chichester, UK: Wiley.
40. Matthews JNS, 2006, Introduction to Randomized Controlled Clinical Trials, 2nd Edition. Boca Raton: Chapman & Hall/CRC.
41. Meyer UA, 2002, Introduction to pharmacogenomics: Promises, opportunities, and limitations. In Licinio J, Wong M-L (Eds), Pharmacogenomics: The Search for Individualized Therapies. Manheim, Germany: Wiley-VCH, 1-8.
42. Molzon JA, 2006, Common technical document: The changing face of the new drug application. In Smith CG, O'Donnell JT (Eds), The Process of New Drug Discovery and Development, 2nd Edition, New York, NY: Informa Healthcare, 473-479.
43. Monkhouse DC, 2006a, The clinical trials material professional: A changing role. In Monkhouse DC, Carney CF, Clark JL (Eds), Drug Products for Clinical Trials, 2nd Edition. Boca Raton: Taylor & Francis, 1-19.
44. Monkhouse DC, 2006b, Manufacturing and clinical medicine trends for the clinical trials material professional. In Monkhouse DC, Carney CF, Clark JL (Eds), Drug Products for Clinical Trials, 2nd Edition. Boca Raton: Taylor & Francis, 21-68.
45. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA, 1991, Variability of the QT measurement in health men: With implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. American Journal of Cardiology, 67:774-776.
46. National Institutes of Health, Department of Health and Human Services, 2004, The seventh report of the Joint National Committee [JNC 7] on prevention, detection, evaluation, and treatment of high blood pressure. NIH Publication No. 04-5230.
47. Nissen SE, Wolski K, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine, 356:2, 457-2, 471.
48. Oliver JJ, Webb DJ, 2003, Surrogate endpoints. In Wilkins MR (Ed), Experimental Therapeutics. Boca Raton: Martin Dunitz/Taylor & Francis Group, 145-165.
49. Olsson S, Meyboom R, 2006, Pharmacovigilance. In Mulder GJ, Dencker L (Eds), Pharmaceutical Toxicology. London: Pharmaceutical Press.
50. Piantadosi S, 2005, Clinical Trials: A Methodologic Perspective, 2nd Edition. Hoboken, NJ: Wiley.
51. Primrose SB, Twyman RM, 2006, Genomics: Applications to Human Biology. Oxford: Blackwell Publishing.
52. Prokscha S, 2007, Practical Guide to Clinical Data Management, 2nd Edition. Boca Raton: Taylor & Francis.
53. Rock EP, Finkle J, Fingert HJ, et al., 2009, Assessing proarrhythmic potential of drugs when optimal studies are infeasible. American Heart Journal, 157:827-836.
54. Rothstein MA (Ed), 2003, Preface. Pharmacogenomics: Social, Ethical, and Clinical Dimensions. Hoboken, NJ: Wiley-LISS.
55. Shah RR, 2007, Cardiac repolarization and drug regulation: Assessing cardiac safety 10 years after the CPMP guidance. Drug Safety, 30:1, 093-1, 110.
56. Soloviev M, Barry R, Terrett J, 2004, Chip-based proteomics technology. In Rapley F, Harbron S (Eds), Molecular Analysis and Genome Discovery. Hoboken, NJ: Wiley.
57. Spiegelhalter DJ, Abrams KR, Myles JP, 2004, Bayesian Approaches to Clinical Trials and Healthcare Evaluation. Hoboken, NJ: Wiley.
58. Spilker B, 2009, Guide to Drug Development: A Comprehensive Review and Assessment. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins.
59. Tsong Y, Chen C-W, Chen WJ, et al., 2006, Stability studies of pharmaceuticals. In Buncher CR, Tsay J-Y (Eds), Statistics in the Pharmaceutical Industry, 3rd Edition. Roca Raton: Chapman & Hall/CRC, 391-419.
60. Turner JR, 2009a, Interpreting the interval: The design, methodology, analysis, and interpretation of the ICH E14 thorough QT/QTc study. European Pharmaceutical Contractor, September issue, 84-86.
61. Turner JR, 2009b, Drug safety, medication safety, patient safety: An overview of recent FDA initiatives and guidances. Regulatory Rapporteur, April issue, 4-8.
62. Turner JR, 2010, Integrated cardiovascular safety: Expanding our assessment horizons for prospectively excluding unacceptable cardiovascular risks. Applied Clinical Trials, June issue, 76-79.
63. Turner JR, Caveney S, 2010, Regulatory landscapes for future antidiabetic drug development (Part II): EMA Guidance on Assessment of Cardiovascular Risks, Journal for Clinical Studies, March issue, 38-40.
64. Turner JR, Satin L, 2009, Making sense of biostatistics: Assessing drug cardiac safety. Journal of Clinical Research Best Practices, May issue. [See http://firstclinical.com/journal/2009/0905-Biostatistics9.pdf]
65. Voorhees J, Scheipeter ME, 2005, Case report form development. In Schuster DP, powers WJ (Eds), Translational and Experimental Clinical Research. Philadelphia: Lippincott Williams & Wilkins, 122-135.
66. Walsh G, 2003, Biopharmaceuticals: Biochemistry and Biotechnology. Chichester, UK: Wiley.
67. Watson JD, 2004. DNA: The Secret of life. New York, NY: Alfred A. Knopf.
68. Whitehead A, 2002, Meta-analysis of Controlled Clinical Trials. Hoboken, NJ: Wiley.
69. Cartwright AC, Matthews BR (Eds), 2009, International Pharmaceutical Product Registration. New York, NY: Informa Healthcare.
70. Mathieu M, 2008, New Drug Development: A Regulatory Overview, 8th Edition. Waltham, MA: Parexel.
71. Tobin JJ, Walsh G, 2008, Medical Product Regulatory Affairs: Pharmaceuticals, Diagnostics, and Medical Devices. Weinheim, Germany: Wiley-VCH.
72. Weinberg S, 2009, Guidebook for Drug Regulatory Submissions. Hoboken, NJ: Wiley.
73. Beal JM Jr, Block JH, 2010, Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 12th Edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins.
74. Ekins S, Xu JJ, 2009, Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools. Hoboken, NJ: Wiley.
75. Faller B, Urban L (Eds), 2010, Hit and Lead Profiling: Identification and Optimization of Drug-like Molecules. Weinheim, Germany: Wiley-VCH.
76. Han C, Davis CB, Wang B (Eds), 2010, Evaluation of Drug Candidates for Preclinical Development: Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology. Hoboken, NJ: Wiley.
77. Cavagnaro, JA (Ed), 2008, Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials. Hoboken, NJ: Wiley.
78. Gad SC (Ed), 2008, Preclinical Development Handbook. Hoboken, NJ: Wiley.
79. Rogge MC, Taft DR (Eds), 2009, Preclinical Drug Development, 2nd Edition. Totowa, NJ: Informa Healthcare.
80. World Health Organization, 2010, Handbook of Good Laboratory Practice (GLP): Quality Practices for Regulated Non-clinical Research and Development. Geneva.
81. Derenzo E, Moss J, 2006, Writing Clinical Research Protocols: Ethical Considerations. Burlington, MA: Elsevier Academic Press.
82. Friedman LM, Furberg CD, De Mets DL, 2009, Fundamentals of Clinical Trials, 3rd Edition. New York, NY: Springer.
83. Machin D, Day S, Green S (Eds), 2006, Textbook of Clinical Trials, 2nd Edition. Chichester, UK: Wiley.
84. Machin D, Fayers P, 2010, Randomised Clinical Trials: Design, Practice and Reporting. Chichester, UK: Wiley-Blackwell.
85. Abdel-aleem SM, 2010, The Design and Management of Medical Device Clinical Trials: Strategies and Challenges. Chichester, UK: Wiley. [While this book focuses on clinical trials of medical devices rather than of drugs, much of its content is highly relevant to drug trials. Issues such as developing protocols, standard operating procedures, site and Principal Investigator selection, subject selection, subject compliance, data management and data analysis are germane in both types of trials.]
86. Piantadosi S, 2005, Clinical Trials: A Methodologic Perspective, 2nd Edition. Hoboken, NJ: Wiley.
87. McFadden E, 2007, Management of Data in Clinical Trials. Hoboken, NJ: Wiley.
88. Robinson M, Cook S, 2006, Clinical Trials Risk Management. Boca Raton, FL: CRC/Taylor & Francis.
89. Spilker B, 2009, Guide to Drug Development: A Comprehensive Review and Assessment. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins [Note: This is a comprehensive book (1277 pages) on the process of drug development. I would like to acknowledge that I have drawn from several of its chapters in the preparation of this chapter.]
90. Woodin E, Schneider JC, 2003, The CRA's Guide to Monitoring Clinical Research. Boston, MA: CenterWatch/Thomas Healthcare.
91. http://www.ctmginc.com/; "CTMG-the world's first Site Specific CRO"
92. Durham TA, Turner JR, 2008, Introduction to Statistics in Pharmaceutical Clinical Trials. London: Pharmaceutical Press.
93. FDA, 2009, Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. [See www.fda.gov]
94. Gad SC (Ed), 2009, Drug Safety Evaluation, 2nd Edition. Hoboken, NJ: Wiley.
95. Turner JR, 2009, Drug safety, medication safety, patient safety: An overview of recent FDA guidances and initiatives. Regulatory Rapporteur, April issue, 4-8.
96. Cook TD, De Mets DL (Eds), 2008, Introduction to Statistical Methods for Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC.
97. Julious SA, Tan S-B, Machin D, 2010, An Introduction to Statistics in Early Phase Trials. Chichester, UK: Wiley-Blackwell.
98. Kay R, 2007, Statistical Thinking for Non-statisticians in Drug Regulation. Chichester, UK: Wiley.
99. Rosenberg MJ, 2010, The Agile Approach to Adaptive Research: Optimizing Efficiency in Clinical Development. Hoboken, NJ: Wiley.
100. Beasley CM Jr, Dmitrienko A, Mitchell MI, 2008, Design and analysis considerations for thorough QT studies employing conventional (10s, 12-lead) ECG recordings, Expert Review in Clinical Pharmacology, 1:815-839.
101. Caveney E, Turner JR, 2010, Regulatory landscapes for future antidiabetic drug development (Part I): FDA guidance on assessment of cardiovascular risk. Journal for Clinical Studies, January issue, 34-36.
102. Turner JR, Durham, 2009, Integrated Cardiac Safety: Assessment Methodologies for Non-cardiac Drugs in Discovery, Development, and Postmarketing Surveillance. Hoboken, NJ: Wiley.
103. Vaibhav S, Karnard DR, Panicker GP, Kothari S, 2009, Update on the evaluation of a new drug for effects on cardiac repolarization in humans: Issues in early drug development. British Journal of Pharmacology, 159:34-38.
104. Gopalaswamy S, Gopalaswamy V, 2008, Combination Products: Regulatory Challenges and Successful Product Development. Boca Raton, FJ: CRC Press.
105. Kulshreshtha AK, Singh ON, Wall GM (Eds), 2010, Pharmaceutical Suspensions: From Formulation to Manufacturing. New York, NY: Springer-Verlag.
106. Niazi SK, 2009, Handbook of Pharmaceutical Manufacturing Formulations. Multi-volume set. New York, NY: Informa Healthcare.
107. Walsh G, 2007, Pharmaceutical Biotechnology: Concepts and Applications. Chichester, UK: Wiley.
108. Mann R, Andrews E, 2007, Pharmacovigilance, 2nd Edition. Hoboken, NJ: Wiley.
109. Medicines and Healthcare Products Regulatory Agency (MHRA), 2009, Good Pharmacovigilance Practice Guide. London: Pharmaceutical Press.
110. Strom BL, Kimmel SE, 2007, Textbook of Pharmacoepidemiology. Hoboken, NJ: Wiley.
111. Waller P, 2010, An Introduction to Pharmacovigilance. Hoboken, NJ: Wiley-Blackwell.